anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PCT No. PCT/RO96/00003 Sec. 371 Date Oct. 3, 1997 Sec. 102(e) Date Oct. 3, 1997 PCT Filed Mar. 14, 1996 PCT Pub. No. WO96/32117 PCT Pub. Date Oct. 19, 1996This bioactive concentrate is an active substance-aqueous solution or lyophilized powder-consisting of anti-hyaluronidase and antiinflammatory mucopolysaccharide polymers and an addition of restitutive and anti-hyaluronidase chondroitinsulphate, which has a pH=4-6 and antihyaluronidase activity. The bioactive concentrate producing method consists in a two-phased treatment of animal-originated connective cartilaginous tissues such as bovine and sheep trachea, umbilical cord, young animal tendons, bowels, testicles or sea organisms, with phenol solution and the solution resulted is concentrated by vacuum evaporation and then defatted; after filtering, the supernatant obtained is treated for deproteinization, the ion excess is removed by passing through ion exchanger column, the alcohol solution is concentrated to remove alcohol until reaching a volume of 70% as against the aqueous solution subject to proteinzation. Drug compsitions contain the bioactive concentrate-solution or in lyophilized state-associated with synergic substances such as: heparin, sodium or lysin acetylsallicylate, ascorbic acid, vitamin E,"I"-like structured water, benzyl alcohol, propylene glycocou, plant extracts (Achillea, Calendula, Matricaria, Plantago, Hypericum) and usual excipients, being conditioned in the form of intramuscular or intraarticular injections, ointment, gel and suppositories. Finally the histamines are removed and chondroitin sulphate is added up to the concentration required.
The subject invention pertains to materials and methods for the prevention and treatment of disease conditions associated with oxidative stress or a compromised reducing environment, including inflammatory bowel diseases such as ulcerative colitis. Another aspect of the subject invention concerns compositions formulated for administration as an enema. The subject invention also concerns compositions formulated for oral administration. Methods of the invention include administration of compounds or compositions of the invention. In one embodiment, compounds or compositions of the invention are rectally instilled in a patient. In another embodiment, compounds or compositions are orally administered.
The invention discloses a multifunctional condom with a hard intercourse aid frame, premature ejaculation can be prevented through the hard intercourse aid frame and a spacer at the top end of the hard intercourse aid frame to protect the phallic genital zone and under the therapeutic function of herbal ointment coated on the inner wall of the condom, and moreover, the impotent penis due to the premature ejaculation can keep the erecting state and smoothly enter into the female vagina to have sexual intercourse smoothly through the intercourse aid frame. The intercourse aid condom is composed of a condom 1 and a sexual intercourse aid frame 2; the sexual intercourse aid frame 2 is composed of a supporting ring 3, a supporting rod 4, a glans clip 5, etc.; in order to protect the genital organs of male and female and avoid the foreign body sensation, the periphery of the sexual intercourse aid frame 2 is wrapped by flesh imitation soft substances such as silicon rubber, etc. The men with impotence, premature ejaculation, heart diseases and no sexual intercourse for a long time, the middle and aged people with sexual hypofunction and the face-loving newly-married normal men, etc. can use the condom securely during the sexual intercourse. The multifunctional condom is convenient, handy and comfortable in use.
The patient will receive 1) amiodarone 150mg bolus over ten minutes followed by intravenous (IV) 1mg/min for 6 hours and then 0.5mg/min for 18hours, and 2) direct current cardioversion (DCC) at the completion of initial 6 hour IV bolus or within 24 hours of new onset of atrial fibrillation. Patient will be placed on by mouth amiodarone 400mg three times daily for seven days, then 400mg twice daily for seven days, then 400mg once daily for seven days, then 200mg daily until stop date which will be by provider discretion after discharge from ICU. If the patient does not convert to a normal sinus rhythm with routine DCC then they will remain in the rhythm-control strategy to receive amiodarone as directed. Amiodarone may be extended at discretion of provider for 30 days with discontinuation if adverse effects. If no contraindications, anticoagulation will be recommended prior to DCC with enoxaparin 1mg/kg every 12 hours.
Evaluation and treatment of NUEDEXTA overdose is based on experience with the individual components, dextromethorphan and quinidine. Metabolism of the dextromethorphan component of NUEDEXTA is inhibited by the quinidine component, such that adverse effects of overdose due to NUEDEXTA might be more severe or more persistent compared to overdose of dextromethorphan alone.

During development of NUEDEXTA, dose combinations of dextromethorphan/quinidine containing up to 6-times higher dextromethorphan dose and 12-times higher quinidine dose were studied. The most common adverse events were mild to moderate nausea, dizziness, and headache.

The most important adverse effects of acute quinidine overdose are ventricular arrhythmias and hypotension. Other signs and symptoms of overdose may include vomiting, diarrhea, tinnitus, high-frequency hearing loss, vertigo, blurred vision, diplopia, photophobia, headache, confusion, and delirium. 

While therapeutic doses of quinidine for treatment of cardiac arrhythmia or malaria are generally 10-fold, or more, higher than the dose of quinidine in NUEDEXTA, potentially fatal cardiac arrhythmia, including torsades de pointes, can occur at quinidine exposures that are possible from NUEDEXTA overdose.

Adverse effects of dextromethorphan overdose include nausea, vomiting, stupor, coma, respiratory depression, seizures, tachycardia, hyperexcitability, and toxic psychosis. Other adverse effects include ataxia, nystagmus, dystonia, blurred vision, and changes in muscle reflexes. Dextromethorphan may cause serotonin syndrome, and this risk is increased by overdose, particularly if taken with other serotonergic agents, SSRIs or tricyclic antidepressants.
Systems, methods and compositions relating to delivering synthetic polymer formulations to the body are described, which can be used by a range of medical personnel including those with minimal experience and training. Under some embodiments, the present invention relates to systems and devices for delivering polymer formulations to a body cavity (e.g. peritoneal cavity) to reduce or stop bleeding. Under some embodiments, an initial percutaneous access pathway is first formed using a delivery device with a probe and needle mechanism that automatically stops the advance of the device upon insertion into a body cavity or space, thus minimizing user error and improving patient safety. The hollow probe then allows transmission of polymer, mixed with gas and/or additional substances, from a holding chamber or canister to flow through the device and hollow probe into the patient's anatomic cavity or space of interest, stopping expansion when the device senses the appropriate pressure. Once reaching the body cavity, the polymer formulation functions to reduce and/or stop bleeding.
Participants will receive a "core" intervention which will include a basic version of the StandUPTV app and a Fitbit watch to use throughout the 16-week intervention.The Fitbit will provide device-based behavioral feedback through the StandUPTV self-monitoring component. SST feedback will be Self-monitoring will provide passive and objective feedback regarding SST behaviors and MVPA drawn from Fitbit and SCREENTIME sources. StandUPTV will also contain basic education including information on the risks of SST and tips for reducing SST. As part of this education, all participants will be provided a behavioral target of reducing their SST by 50% from their baseline. This target will be customized for the participant within StandUPTV based on a baseline week of observation.
Participants will complete 22.5 hours of cognitive training exercises over 6-weeks (training 5 times a week) using an app-based program, BrainHQ. BrainHQ is based on a previous neuroscience-based cognitive training program shown to improve cognition in several different randomized controlled studies with other clinical populations. The investigators will use a suite of BrainHQ exercises designed to target and ameliorate cognitive disruptions in 4 cognitive domains (see main outcome). The investigators will employ basic exercises that focus on increasing processing efficiency in the auditory and visual perceptual and working memory domains, as well as exercises that target impulsivity and cognitive biases. Exercises will be packaged into 4 modules (attention skills, memory skills, executive functioning skills, cognitive control skills) comprised of 4 exercises each. All participants will progress through the same fixed schedule of modules.
Vaginal dispenser comprises a plurality of containers having walls that are at least partly of semi-permeable membranes and releasable contg. a biologically active agent (I), with a thin flexible planar seal fin encompassing and receiving the outer surface of the containers at a central location to keep them in an arcuate flat sequence. Pref. the containers are made of cellulose. Used for delivering (I), esp. contraceptives and medicaments into the vagina; the dispenser is easily fitted by the user and can remain in the vagina during intercourse and during menstruation. Pref. there is one or more hinge points on the seal fin to give additional flexibility, and the dispenser is pref. circular. Pref. in such a circular dispenser the containers are made of cellulose and are semi-permeable membranes. The containers may be filled with an aqs. soln. of a micelle-forming spermicidal surfactant at a concn. above the critical micelle concn. of the surfactant. Suitable cellulose containers are of material of dry thickness 5-25 mu and swollen thickness 10-50 mu.
FIELD: medicine. SUBSTANCE: transdermal system consists of integumentary, glue, reservoir and, if necessary, protective layers. Reservoir layer has polymeric material taken from a group of block-copolymer on the basis of styrene and 1,3-diene, polyisobutylene, polymers on the basis of acrylate and/or methacrylate and esters of hydrogenated colophony. The sources of reservoir layer polymeric material: linear block-copolymer styrene-isoprene-styrene, linear block-copolymer styrene-butadiene-styrene, copolymer of 2-ethylhexylacrylate with vinyl acetate, acrylic acid and titanium-chelate-ester, copolymer of 2-ethylhexylacrylate with vinyl acetate and acrylic acid, or copolymer of diethylaminoethylmethacrylate and neutral ester of methacrylic acid. The source of hydrogenated colophony ester: its methyl- or glycerol ester, dioxylcyclohexane, triglyceride or isopropylmyristate, or di-n-butyladipate. Transdermal system releases physostigmine for at least 24 h and retains stability of physostigmine at storage for 3-6 months. EFFECT: increases period of physostigmine releasing, enhanced stability at storage. 2 cl
A method and apparatus for censoring selected information. A mobile device is registered with a medical system. The medical system includes a display device. A trigger is received from the mobile device at the medical system. A display on the display device is modified in response to the received trigger. Selected information in the display is censored in the modified display. Alternatively, an image of a display on the display device is generated with selected information censored in response to receiving the trigger. The image of the display with the selected information censored is sent to the mobile device.
Methods for reducing or inhibiting the irreversible inactivation of water-soluble biologically active agents in biodegradable polymeric delivery systems which are designed to release such agents over a prolonged period of time, such as PLGA delivery systems are provided. The method comprises preparing PLGA delivery systems whose microclimate, i.e. the pores where the active agent resides, uniformly or homogenously maintain a pH of between 3 and 9, preferably between 4 and 8, more preferably between 5 and 7.5 during biodegradation. Depending on the size of the delivery system, and the initial bulk permeability of the polymer, this result is achieved by (a) incorporating a water-soluble carrier into the delivery system, (b) incorporating a select basic additive (or antacid) into the delivery system, (c) incorporating both a water soluble carrier and a select basic additive into the delivery system, (d) adding a pore forming molecule for increasing the rate of release of low molecular weight monomers and oligomers into the delivery system, (e) using a PLGA polymer with reduced glycolide content, i.e. PLGA with from 100% to 75% lactide and 0 to 25% glycolide) (f) using a microencapsulation method that yields a more extensive pore-network, e.g. oil-in-oil emulsion-solvent extraction as opposed to water-in-oil-in water-solvent evaporation method, and (g) combinations thereof.
Patients with atrial fibrillation that undergo a standard of care, clinically approved, left atrial appendage closure will be considered for study. All patients will be followed for 24 months, and will be assessed at the 3-, 6-, 12-, 18- and 24-months post-left atrial appendage closure as well as other visits deemed necessary for clinical care. All subjects will undergo protocol-specified laboratory tests and will complete 6 standard, validated questionnaires at each follow-up visit, except at the 3-month visit when only one questionnaire will be administered.
The present invention belongs to the field of oral cleaning health-caring object, and especially to a gargle tablet composition and a preparing method thereof. The present invention adopts a quick oral disintegrating technique to cause that a tablet with a certain size is disintegrated in oral cavity in scores of seconds. The active component is disintegrated quickly. The dissolved amount in 30 seconds can be higher than 75%. The functions of dental-cavity prevention and/or bacterium restriction and/or whitening are exerted. The efficacy of one tablet is same to the efficacy of 10-20ml of gargle water. The quick oral disintegrating gargle table related by the invention is a non-effervescence system rapid oral disintegrating tablet and has the advantages of no high requirement for producing condition and packaging material, and low cost. The producing condition and packaging material of common tablet can be adopted. The quick oral disintegrating gargle table related by the invention also has the advantages of easy carrying, simple using method and innovation to a novel oral cleaning health-caring concept. The quick oral disintegrating gargle table related by the invention satisfies the requirement of people in modern life, especially the office worker and the person who often go on errand or visit or in long-time outdoor action to the oral cleaning health-caring.
Sudden unexpected death in epilepsy (SUDEP) is responsible for most epilepsy-related deaths. It is mainly related to unwitnessed nocturnal convulsions, either focal to bilateral or generalised tonic-clonic seizures (TCS). Targeted preventive strategies are currently lacking as underlying mechanisms are largely unknown. Antiseizure medications (ASMs) modulate SUDEP risk through seizure reduction, but it is yet undetermined whether individual ASMs or other medications could also influence the internal SUDEP cascade. Seizure detection devices (SDD) may offer an alternative strategy by preventing TCS from being unwitnessed. Here, we critically evaluated the current evidence on the influence of ASMs, non-epilepsy concomitant drugs and SDD on SUDEP occurrence. We found no robust evidence for the effect of starting ASMs on SUDEP beyond TCS control, but we found some indications of a protective effect for polytherapy. We found no signs that specific ASMs exert a risk for SUDEP. One study suggested a possible protective effect of levetiracetam requiring further investigation. Only a few small studies addressed the association between non-epilepsy concomitant drugs and SUDEP, with no consistent effect for psychotropic medications and one more extensive study suggesting a lower risk among statin users. We only found indirect evidence indicating a protective effect for enhancing nocturnal supervision without explicitly addressing the impact of SDD on SUDEP occurrence. Further work is needed to explore the potential of ASMs and other interventions to modulate SUDEP risk, and they should accurately account for TCS frequency, polypharmacy and markers of non-adherence.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, oncology, and can be used for conservative treatment and relapse prevention of virus-associated precancer and early cancer cervix. Photodynamic therapy is carried out for this purpose. A compound photosense is used as a photosensitiser. The energy density of laser radiation is 150 J/cm2. At that the cervical canal is affected with a quartz light guide with a cylindrical diffuser. The vaginal area of cervix is affected with microlens. ^ EFFECT: method enables to achieve treatment effect equivalent to surgical due to neutralisation of etiological factor of cervical carcinogenesis, to carry out surgical service at aggravated somatic status, to avail of the opportunity of full generative function. ^ 2 ex
The invention discloses a Chinese medicinal composition for treating excess fire type cholecystitis. The Chinese medicinal composition is prepared from the following crude medicaments in part by weight: 10 to 15 parts of rhubarb, 8 to 12 parts of gentian, 25 to 35 parts of patrinia, 8 to 12 parts of mirabilite, 25 to 35 parts of plaster stone, 8 to 12 parts of gardenia and 25 to 35 parts of oriental wormwood. The compatibility idea of the Chinese medicinal composition is that: the rhubarb and the mirabilite are used as monarch medicaments and the gentian, the patrinia, the plaster stone, the gardenia and the oriental wormwood are used as ministerial medicaments. The composition fulfils the aim of treating the excess fire type cholecystitis by bowel relaxation, intense heat purging and detoxification. The medicament of the invention is decocted by adding water by a conventional method and prepared into aqua and can also be prepared into powder, tablets and capsules by using the conventional method. The Chinese medicament for treating the excess fire type cholecystitis has the advantages of unique compatibility, skillful medication, obvious effect on the treatment of the excess fire type cholecystitis, good therapeutic effect, low therapy cost and no side effect.
Patients receive cetuximab IV over 60-120 minutes on days 1 and 15. Patients who fail cetuximab as a single agent may receive single agent tivantinib PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
BACKGROUND: The results of current studies on metabolic-dysfunction associated steatotic liver disease (MASLD)-related diseases, cognition and dementia are inconsistent. This study aimed to elucidate the effects of MASLD-related diseases on cognition and dementia.
METHODS: By using single-nucleotide polymorphisms (SNPs) associated with different traits of NAFLD (chronically elevated serum alanine aminotransferase levels [cALT], imaging-accessed and biopsy-proven NAFLD), metabolic dysfunction-associated steatohepatitis, and liver fibrosis and cirrhosis, we employed three methods of mendelian randomization (MR) analysis (inverse-variance weighted [IVW], weighted median, and MR-Egger) to determine the causal relationships between MASLD-related diseases and cognition and dementia. We used Cochran's Q test to examine the heterogeneity, and MR-PRESSO was used to identify outliers (NbDistribution = 10000). The horizontal pleiotropy was evaluated using the MR-Egger intercept test. A leave-one-out analysis was used to assess the impact of individual SNP on the overall MR results. We also repeated the MR analysis after excluding SNPs associated with confounding factors.
RESULTS: The results of MR analysis suggested positive causal associations between MASLD confirmed by liver biopsy (p of IVW = 0.020, OR = 1.660, 95%CI = 1.082-2.546) and liver fibrosis and cirrhosis (p of IVW = 0.009, OR = 1.849, 95%CI = 1.169-2.922) with vascular dementia (VD). However, there was no evidence of a causal link between MASLD-related diseases and cognitive performance and other types of dementia (any dementia, Alzheimer's disease, dementia with lewy bodies, and frontotemporal dementia). Sensitivity tests supported the robustness of the results.
CONCLUSIONS: This two-sample MR analysis suggests that genetically predicted MASLD and liver fibrosis and cirrhosis may increase the VD risk. Nonetheless, the causal effects of NAFLD-related diseases on VD need more in-depth research.
Children of age group 6-12 will be randomly divided in 3 groups, First group will be Placebo , second group will be nitrous oxide end tidal 20-30% and third group will be nitrous oxide 60-70%. Each group will be divided into 2 subgroups randomly with either a flavored or unflavored mask for induction.

All children will be told a joke before the mask is applied, with the answer provided after the end-tidal nitrous oxide concentration reaches the randomized concentration (0, 30 or 60%) for at least one minute. At that point, the child will randomized to be either shown a picture of one of four animals (predetermined randomly) or a food will be stated aloud. For the animal, the child will be asked to name the animal aloud. The child's response (yes or no to a response and whether the item is correctly named) will be recorded. If the child does not respond, the name of the animal will be stated out loud. For the food, one of four foods will be named aloud and child will be asked to repeat the name. The child's response (named or not) will be recorded. Anesthesia will continue with the designated nitrous oxide concentration combined with 8% Sevoflurane.

When the child is ready for discharge from the recovery room and recovered from anesthesia, a nurse or doctor who is blinded to the treatment group assignment will ask the child to recall the joke and answer. The child will then be asked if they were shown any animals and if so, which animal? If the child cannot recall an animal, the child will be asked to name the first animal that comes to mind. The child will then be shown pictures of four animals and asked to identify one. The child will be asked if they heard any foods when they went to sleep? If the child cannot recall hearing any foods recited, the first letter of the food will be shown: B _ _ _ _ _ . If the child does not recall any foods, then the child will be given the names of four foods that begin with the letter B and asked to pick one. Finally, the child will be asked about any odors in the mask during anesthesia. If he/she does not recall, then four odors will be read out and the child asked to identify any one. Additionally, the children will be asked whether they recall any odors on the mask as they were anesthetized. The order of items questioned in the recovery period will follow the same order as in the OR.
Sending to the community referring physician by the emergency department an discharge report containing the reason for emergency consultations (report currently made as part of the treatment). Within 72 hours (working hours), the Emergency Clinical Pharmacist contacts the referring physician and the patient's community pharmacist to discuss how to manage the ADE. In parallel, a second report, summary of the ADE (ADE-report), is sent to them. The ADE-report, written and validated by the investigators (emergency physician and clinical pharmacist), includes the type of ADE, the suspected drug(s) and other recommendations: therapeutic modification, referral to specialized consultations (geriatrics ...).